1-ethyl-8-(2-ethyl-4-methyl-1H-imidazol-1-yl)-3-methylimidazo[1,5-a]quinoxalin-4(5H)-one | 133307-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-ethyl-8-(2-ethyl-4-methyl-1H-imidazol-1-yl)-3-methylimidazo[1,5-a]quinoxalin-4(5H)-one
• 英文别名: 1-ethyl-8-(2-ethyl-4-methylimidazol-1-yl)-3-methyl-5H-imidazo[1,5-a]quinoxalin-4-one
• CAS: 133307-36-5
• 化学式: C₁₉H₂₁N₅O
• 分子量: 335.409
• InChiKey: WSEIXVLFQCKSDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,4-二氟硝基苯 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 乙醇 、 乙腈 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 27.5h， 生成 1-ethyl-8-(2-ethyl-4-methyl-1H-imidazol-1-yl)-3-methylimidazo[1,5-a]quinoxalin-4(5H)-one
  参考文献：
  名称：

  Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogs

  摘要：

  A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(H-1-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterases (PDE's) and evaluated for their vasorelaxant and positive inotropic activities in vitro. In general, compounds having potent PDE inhibitory activity also possessed good inotropic and vasodilator activity, although linear correlations between these activities could not be established.

  DOI：

  10.1021/jm00113a002

文献信息

• Imidazoquinoxalinones, their aza analogs and process for their preparation
  申请人：BERLEX LABORATORIES, INC.

  公开号：EP0400583A1

  公开（公告）日：1990-12-05

  This invention relates to novel imidazoquinoxalinones and their aza analogs and to a process for their preparation. The compounds of this invention have been found to have inodilatory, vasodilatory, venodilatory and other pharmacologic effects.

  本发明涉及新型咪唑喹喔啉酮及其氮杂类似物，以及其制备工艺。已发现本发明的化合物具有扩张血管、扩张静脉和其他药理作用。
• US5055465A
  申请人：——

  公开号：US5055465A

  公开（公告）日：1991-10-08
• US5166344A
  申请人：——

  公开号：US5166344A

  公开（公告）日：1992-11-24
• Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogs
  作者：David D. Davey、P. W. Erhardt、E. H. Cantor、S. S. Greenberg、W. R. Ingebretsen、J. Wiggins

  DOI：10.1021/jm00113a002

  日期：1991.9

  A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(H-1-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterases (PDE's) and evaluated for their vasorelaxant and positive inotropic activities in vitro. In general, compounds having potent PDE inhibitory activity also possessed good inotropic and vasodilator activity, although linear correlations between these activities could not be established.